ODN 2087

Name: ODN 2087
SKU: CGON-06

For research use only. Not intended for any clinical use.

Cat.No.

CGON-06

Description

CpG oligodeoxynucleotides (or CpG ODNs) are synthetic oligonucleotides that contain unmethylated CpG motifs. CpG ODN can bind to and activate a Toll-like receptor 9 (TLR9) and leading to strong immunostimulatory effects. So far 3 major classes of CpG ODNs have been identified, based on their structural and biological characteristics, and are designated Type A, Type B, and Type C. Type A ODNs, which feature a central palindromic CpG-containing phosphodiester (PO) structure followed by a phosphorothioate (PS) homopolymeric G-stretch, are robust inducers of interferon-α (IFN-α) production and dendritic cell maturation. Type B ODNs, in contrast, contain a full phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but stimulate weakly IFN-α secretion. Type C ODNs, combine the properties of both Type A and B, and are characterized by their complete PS backbone and palindromic CpG-containing motifs. Type C ODNs induce strong IFN-α production from pDC and B cell stimulation.
ODN 2087 can be used as a sequence control for ODN 2088. ODN 2087 inhibits TLR7- and TLR8-mediated signaling but not TLR9-mediated signaling.

Features

• Product format: Lyophilized product
• Sequence: 5'-tcctgagcttgaagt-3' (lower case letters are phosphorothioate)
• Specificity: Control for ODN 2088, which inhibits TLR7- and TLR8-mediated signaling but not TLR9-mediated signaling.

Storage

Store lyophilized product at -20°C. Upon reconstitution, aliquots should be stored at -20°C and are stable for 6 months. Avoid repeated freeze-thaw cycles.

Publications

Q & A

Customer Reviews

Customer Q&As

How does ODN 2087 specifically target and inhibit the toll-like receptor (TLR) signaling pathway, and what are its mechanistic effects at the molecular level?

A: ODN 2087 is a synthetic oligodeoxynucleotide that acts as a TLR7 and TLR9 antagonist. It binds to these receptors, preventing the recognition and binding of their natural ligands. At the molecular level, ODN 2087 competes with stimulatory DNA or RNA motifs and inhibits the subsequent TLR-mediated activation of immune responses.

Are there any off-target effects or unintended receptor interactions when using ODN 2087 in cellular models?

A: While ODN 2087 is designed to specifically antagonize TLR7 and TLR9, like any other compound, there may be potential off-target effects. It's essential for researchers to run control experiments, including specificity assays, to determine the exact specificity of ODN 2087 in their experimental model.

How does the inhibitory efficiency of ODN 2087 compare with other TLR antagonists available in the market?

A: ODN 2087 has demonstrated significant efficacy in inhibiting TLR7 and TLR9 signaling. While it exhibits potent inhibition, a direct comparison with other TLR antagonists requires a side-by-side analysis under standardized conditions. The efficiency might also vary based on experimental setups and biological models.

What are the optimal working concentrations for ODN 2087 in both in vitro and in vivo experiments to achieve effective TLR7 and TLR9 inhibition?

A: The optimal concentration of ODN 2087 can vary based on the experimental model and the specific biological context. In vitro studies typically employ micromolar concentrations, while in vivo applications might require dose-titration studies to determine the effective concentration that offers maximal inhibition with minimal off-target effects.

Are there any documented adverse reactions or cytotoxic effects associated with the use of ODN 2087 in primary cells or animal models?

A: As with any bioactive compound, potential cytotoxic effects or adverse reactions might arise with high concentrations or prolonged exposure to ODN 2087. It's crucial for researchers to conduct cytotoxicity assays and monitor the general health and behavior of treated animals to ensure safety and compound tolerance.

Given that ODN 2087 inhibits TLR7 and TLR9 signaling, how does it affect the overall immune response, especially in the context of viral infections or autoimmune conditions?

A: By antagonizing TLR7 and TLR9, ODN 2087 can dampen the immune response to certain DNA or RNA motifs. In the context of viral infections, it might attenuate excessive inflammatory responses, potentially preventing tissue damage. Conversely, in autoimmune conditions where TLR signaling might be aberrantly activated, ODN 2087 can act as a therapeutic agent to modulate the immune response.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

First Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *